MiNK Therapeutics(INKT) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immunemediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m ...